Mergers & Acquisitions ·
Passage Bio stockholders approve merger with Remix Therapeutics and authorize reverse split
PASGPassage BIO, Inc.
Passage Bio, Inc. stockholders approved key proposals at a Special Meeting on November 5, 2026, including the issuance of Passage Bio Common Stock to securityholders of Remix Therapeutics, Inc., which will result in a change of control of Passage Bio. Shareholders also authorized an amendment to effect a reverse stock split with a ratio ranging from 1-for-2 to 1-for-10 and approved amendments to the certificate of incorporation to change the company's name to Remix Therapeutics, Inc. Additionally, stockholders adopted the Remix Therapeutics, Inc. 2026 Equity Incentive Plan and the 2026 Employee Stock Purchase Plan. Passage Bio, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for rare diseases.